S 8921

Drug Profile

S 8921

Latest Information Update: 28 Feb 2005

Price : $50

At a glance

  • Originator Shionogi
  • Class Antihyperlipidaemics
  • Mechanism of Action Sodium-bile acid cotransporter-inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Hyperlipidaemia

Most Recent Events

  • 31 Jan 2005 Discontinued for Hyperlipidaemia in Japan (PO)
  • 31 Jan 2005 Discontinued - Phase-II for Hyperlipidaemia in Europe (PO)
  • 11 Nov 2002 Phase-II clinical trials in Hyperlipidaemia in Europe (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top